Drug Trial Radar · NCT05662319
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
91
Actual
Start
Feb 1, 2023
Primary completion
Mar 25, 2027
Study completion Jan 25, 2029
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Dec 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, multinational, open-label, one-way cross-over, Phase 3, single-arm study for treatment of hemophilia. The purpose of this study is to measure the frequency of treated bleeding episodes with fitusiran in male adult and adolescent (≥12 years old) participants with hemophilia A or B, with or without inhibitory antibodies to factor VIII or IX who have switched from their prior standard of care treatment. The total study duration will be up to approximately 50 months (200 weeks, 1 study month is equivalent to 4 weeks) and will include: * A screening period up to approximately 60 days, * A standard of care (SOC) period of approximately 6 study months (24 weeks), * A fitusiran treatment period of approximately 36 study months (144 weeks), * An antithrombin (AT) follow-up period of approximately 6 study months (24 weeks) but may be shorter or longer depending on individual participants AT recovery. The frequency for telephone visits will be approximately every 2 weeks. For site visits the frequency will be approximately every 8 weeks during the SOC period and approximately every 4 weeks during the fitusiran treatment period. If applicable and if allowed by local regulation, home and/or remote visits may be conducted during the study
Conditions
- Hemophilia
Interventions
FitusiranDrug
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous (SC)
Clotting factor concentrates (CFC) or bypassing agents (BPA)Drug
* Coagulation factor VIII (ATC code: B02BD02) * Coagulation factor IX (ATC code: B02BD04) * Coagulation factor VIIa (ATC code: B02BD08) * Factor VIII inhibitor bypassing activity (ATC code: B02BD03) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
Antithrombin concentrate (ATIIIC)Drug
Antithrombin III (ATC code: B01AB02) Pharmaceutical form: Solution for infusion Route of administration: Intravenous (IV)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized bleeding rate (ABR) in the fitusiran primary efficacy periodTime frame: Day 169 to Day 505 (since the first dose of fitusiran)
Locations
50 sites in 17 countries. Site status is shown where the registry gives one.
Center for Inherited Blood Disorders (CIBD) Site Number : 8400012
Orange, California
M Health Fairview University of Minnesota Medical Center - West Bank- Site Number : 8400016
Minneapolis, Minnesota
Hackensack University Site Number : 8400009
Hackensack, New Jersey
Northwell Health Hemostasis and Thrombosis Center Site Number : 8400015
New Hyde Park, New York
University Hospitals of Cleveland Site Number : 8400001
Cleveland, Ohio
UPMC Children's Hospital of Pittsburgh-4401 Penn Ave Site Number : 8400017
Pittsburgh, Pennsylvania
Children's Medical Center Dallas- Site Number : 8400018
Dallas, Texas
Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400002
Houston, Texas
Investigational Site Number : 1240001
Hamilton, Ontario, Canada
Investigational Site Number : 1240002
Hamilton, Ontario, Canada
Investigational Site Number : 1240004
Toronto, Ontario, Canada
Investigational Site Number : 1560003
Beijing, China
Investigational Site Number : 1560001
Guangzhou, China
Investigational Site Number : 1560002
Jinan, China
Investigational Site Number : 2500003
Le Kremlin-Bicêtre, France
Investigational Site Number : 2500002
Lille, France
Investigational Site Number : 2500001
Paris, France
Investigational Site Number : 2760001
Berlin, Germany
Investigational Site Number : 2760002
Hamburg, Germany
Investigational Site Number : 3000001
Athens, Greece
Investigational Site Number : 3000002
Athens, Greece
Investigational Site Number : 3560004
Bangalore, India
Investigational Site Number : 3560007
Bhubaneswar, India
Investigational Site Number : 3560001
Pune-411011, India
Investigational Site Number : 3560006
Punjab, India
Investigational Site Number : 3560003
Vellore, India
Investigational Site Number : 3800001
Milan, Italy
Investigational Site Number : 3800003
Rozzano, Milano, Italy
Investigational Site Number : 3920003
Nagoya, Aichi-ken, Japan
Investigational Site Number : 3920001
Kashihara-shi, Nara, Japan
Investigational Site Number : 3920002
Saitama-shi, Saitama, Japan
Investigational Site Number : 4840004
Chihuahua City, Mexico
Investigational Site Number : 4840001
Veracruz, Mexico
Investigational Site Number : 4840002
Monterrey, Nuevo León, Mexico
Investigational Site Number : 6160002
Krakow, Lesser Poland Voivodeship, Poland
Investigational Site Number : 6160004
Lodz, Lódzkie, Poland
Investigational Site Number : 6160001
Warsaw, Masovian Voivodeship, Poland
Investigational Site Number : 6820002
Jeddah, Saudi Arabia
Investigational Site Number : 7100003
Johannesburg, South Africa
Investigational Site Number : 7100001
Parktown, South Africa
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.